Idasanutlin - Roche

Drug Profile

Idasanutlin - Roche

Alternative Names: RG-7388; RO-5503781

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Mayo Clinic; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; University of Glasgow
  • Class Aminobenzoic acids; Antineoplastics; Pyrrolidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Polycythaemia vera
  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Prostate cancer
  • Phase I Solid tumours
  • No development reported Cancer; Essential thrombocythaemia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Monotherapy) in Canada (PO, Tablet)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Monotherapy) in France (PO, Tablet)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Monotherapy) in United Kingdom (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top